We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+71.22%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$327M
Cap. Flow
+$45.1M
Cap. Flow %
6.18%
Top 10 Hldgs %
57.09%
Holding
84
New
23
Increased
22
Reduced
20
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$40.8M
2
UTHR icon
United Therapeutics
UTHR
+$26.2M
3
HSKA
Heska Corp
HSKA
+$20M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$18.2M
5
AZN icon
AstraZeneca
AZN
+$10.8M

Top Sells

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$29.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$27.8M
3
DHR icon
Danaher
DHR
+$20.4M
4
APLS
Apellis Pharmaceuticals
APLS
+$15.4M
5
GSK icon
GSK
GSK
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 81.4%
2 Miscellaneous 16.98%
3 Communication Services 1.62%
4 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCPH
51
DELISTED
scPharmaceuticals
SCPH
$1.82M 0.25%
247,419
+115,000
+87% +$1.01M
PRTA icon
52
Prothena Corp
PRTA
$479M
$1.59M 0.22%
+152,213
New +$1.69M
CYH icon
53
Community Health Systems
CYH
$413M
$1.48M 0.2%
492,272
-88,078
-15% -$283K
CYCN icon
54
Cyclerion Therapeutics
CYCN
$17.7M
$1.46M 0.2%
12,383
-4,474
-27% -$374K
ZYME icon
55
Zymeworks
ZYME
$2.02B
$1.44M 0.2%
+40,000
New +$1.47M
CARM
56
DELISTED
Carisma Therapeutics
CARM
$1.44M 0.2%
100,000
+35,000
+54% +$472K
TARA icon
57
Protara Therapeutics
TARA
$226M
$1.36M 0.19%
46,310
+13,832
+43% +$428K
XOMA
58
DELISTED
Xoma
XOMA
$1.27M 0.17%
+64,056
New +$1.41M
SLDB icon
59
Solid Biosciences
SLDB
$1.05B
$1.19M 0.16%
+27,135
New +$1.13M
KALV
60
DELISTED
KalVista Pharmaceuticals
KALV
$1.09M 0.15%
+89,806
New +$955K
QURE icon
61
uniQure
QURE
$3.38B
$1.03M 0.14%
+22,928
New +$1.35M
DVAX
62
DELISTED
Dynavax Technologies
DVAX
$867K 0.12%
+97,800
New +$494K
TLGT
63
DELISTED
Teligent, Inc
TLGT
$859K 0.12%
354,998
-31,292
-8% -$110K
BNR
64
Burning Rock Biotech
BNR
$107M
$810K 0.11%
+3,000
New +$822K
AL
65
PUT
DELISTED
Air Lease Corp
AL
$586K 0.08%
20,000
– –
RVLP
66
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$532K 0.07%
+79,037
New +$387K
EIGR
67
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$470K 0.06%
1,634
-690
-30% -$203K
IMVT icon
68
Immunovant
IMVT
$8.51B
$299K 0.04%
12,266
-64,600
-84% -$1.38M
ZGNX
69
CALL
DELISTED
Zogenix, Inc.
ZGNX
$149K 0.02%
5,500
– –
AMRN
70
PUT
Amarin Corp
AMRN
$295M
– –
-7,500
Closed -$600K
AQST icon
71
Aquestive Therapeutics
AQST
$630M
– –
-300,000
Closed -$657K
EHTH icon
72
eHealth
EHTH
$38.4M
– –
-3,153
Closed -$444K
IFRX icon
73
InflaRx
IFRX
$329M
– –
-195,488
Closed -$747K
IGMS
74
DELISTED
IGM Biosciences
IGMS
– –
-9,770
Closed -$549K
IOVA icon
75
Iovance Biotherapeutics
IOVA
$3.63B
– –
-90,047
Closed -$2.7M
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Eversept Partners held 84 positions worth $729M, up 81% from $402M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Eversept Partners deployed $45.1M of net new capital in Q2 2020, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was ChemoCentryx, Inc., an estimated $29.3M trimmed.

  • Eversept Partners's largest Q2 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
  • Eversept Partners added most to Heska Corp in Q2 2020, an estimated $20M increase.
  • Eversept Partners's biggest Q2 2020 reduction was ChemoCentryx, Inc., cutting an estimated $29.3M.
  • Eversept Partners fully exited Kadmon Holdings, Inc. in Q2 2020, selling an estimated $4.09M.
  • Eversept Partners's ten largest holdings make up 57% of its $729M portfolio in Q2 2020.
  • Eversept Partners opened 23 new positions and closed 15 in Q2 2020.
  • Eversept Partners's portfolio value rose 81% quarter-over-quarter to $729M.

Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.